论文部分内容阅读
目的探讨Kras基因、BRAF基因与表皮生长因子受体(EGFR)之间的关系,为进一步研究Ras-Raf-MEK-ERK通路导致EGFR-TKI耐药的具体机制奠定基础。方法获取74例经手术治疗,术后未行放化疗和(或)靶向药物治疗的非小细胞肺癌(NSCLC)患者的肿瘤组织标本,检测EGFR各位点,Kras及BRAF基因的突变,并做相关性分析。结果 EGFR exon 19、exon 21与Kras突变存在负相关,(相关系数r分别为-0.345和-0.309,P<0.01)。EGFR与BRAF,Kras与BRAF之间不存在相关性(P>0.01)。结论 EGFR突变与Kras突变呈负相关,与BRAF突变不存在相关性,Kras与Braf突变不相关,提示EGFR、Kras和Braf突变为相互独立的过程。
Objective To investigate the relationship between Kras gene, BRAF gene and epidermal growth factor receptor (EGFR), and lay a foundation for further study of the specific mechanism of Ras-Raf-MEK-ERK pathway leading to EGFR-TKI resistance. Methods Tumor samples of 74 patients with non-small cell lung cancer (NSCLC) who underwent radiotherapy and chemotherapy and / or after surgery were obtained. The mutations of EGFR loci, Kras and BRAF genes were detected and analyzed. Correlation analysis. Results There was a negative correlation between EGFR exon 19, exon 21 and Kras mutation (r = -0.345 and -0.309 respectively, P <0.01). There was no correlation between EGFR and BRAF, Kras and BRAF (P> 0.01). Conclusion EGFR mutation is negatively correlated with Kras mutation, but not with BRAF mutation. Kras is not correlated with Braf mutation, suggesting that EGFR, Kras and Braf mutations are independent of each other.